Vinpocetine
Trade name: vinporal
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 2012 (NCT02011971)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c(n1c1ccccc41)[C@@H]32- Mol. weight
- 350.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL71752 ↗
Also known as
- apovincaminic acid ethyl ester
- ay-27255
- ay-27255
- bravinton
- cavinton
- cavinton
- cavinton
- cavinton
- cavinton
- ceractin
- ceractin
- ceractin
- eburnamenine-14-carboxylic acid, ethyl ester, (3 alpha,16 alpha)-
- ethyl apovincamin-22-oate
- ethyl apovincamin-22-oate
- ethyl apovincaminate
- ethyl apovincaminate
- ethyl apovincaminate, (16alpha)-isomer
- ethyl apovincaminate, 2-oxopentanedioate (1:1)
- ethyl apovincaminate, (3alpha,16alpha)-isomer
- ethyl apovincaminate, 3h-labeled
- ethyl apovincaminate, (+-)-isomer
- ethyl apovincaminate tartrate
- ethyl apovincaminate tartrate (1:1)
- kavinton
- rgh-4405
- tcv-3b
- vinpocetine
- vinpocetine
- vinpocetine
- vinpocetine
- vinpocetine
- vinpocetine
- vinpocetine
- vinporal
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02878772 | Phase 2/Phase 3 (Phase 3) | May 1, 2014 | Nanjing Medical University, Tianjin Medical University |
| NCT02011971 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2012 | Emory University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Nanjing Medical University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Tianjin Medical University | Academic/Hospital | 1 | 0 | 1 | 2014 |
3 organizations
Page 1 / 1